OD3 STOCHASTIC COST-EFFECTIVENESS ANALYSIS OF CHRONIC VENOUS LEG ULCERS—THE CASE OF PROMOGRAN® IN A SWEDISH HEALTH CARE SETTING  by Ghatnekar, O et al.
456 Abstracts
propriate (eg, those with a history of reproductive cancer
or demonstrated intolerance to HRT), and no publicly
subsidised therapeutic options are available in Australia
for such women. The aim of this study was to assess the
cost-effectiveness of raloxifene in preventing osteoporotic
fractures when HRT is inappropriate. METHODS: A
Markov model was developed to compare raloxifene with
no drug therapy in patients who are unable to use HRT.
Separate analyses were performed for those who are 
intolerant of HRT and those unsuitable for HRT due to
a history of reproductive cancer (with a consequent
greater baseline risk of breast cancer). Relative efﬁcacy
assumptions in the model were taken from randomised
controlled trials and the published literature. Primary out-
comes included vertebral fractures, non-vertebral frac-
tures and breast cancer in a cohort with a low bone
mineral density and an average age of 65 years. The
model ran for a period of 30 years, contained nine dis-
crete states and produced cost per quality-adjusted life-
year (QALY) values. Limited memory was incorporated
into the model by separating each fracture health state
into two states, representing a ﬁrst year and then subse-
quent years after fracture. RESULTS: The incremental
cost per QALY gained with raloxifene compared with no
therapy was $33,539 in those who are intolerant of HRT
and $29,780 per QALY in patients with a history of
reproductive cancer. Extensive sensitivity analyses 
indicated the results remained robust. CONCLUSIONS:
Raloxifene is a cost-effective therapy to reduce fracture
risk in postmenopausal women unsuitable for HRT.
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Continuity is a key treatment success factor to reduce
relapse and hospitalisation rates of schizophrenic
patients. Atypical antipsychotics with daily oral adminis-
tration are associated with improved efﬁcacy, tolerability
and compliance compared with older, conventional neu-
roleptics. Similarly, conventional depots have shown 
to reduce the risk of relapse over oral conventional. The
novel long-acting risperidone, administered intramuscu-
larly once every two weeks, is the ﬁrst long-acting for-
mulation of an atypical antipsychotic. OBJECTIVES: To
assess the cost-effectiveness of long-acting risperidone
versus oral olanzapine and haloperidol decanoate in
recently diagnosed schizophrenic patients. METHODS:
A cost-effectiveness analysis is considered. Main assump-
tion is that compliance improvement, thanks to a long-
acting formulation leads to an increased efﬁcacy. A
decision tree model was built with a time horizon of 
2 years. A French payers perspective was adopted.
Outcome probabilities and cost estimates were based on
published data, and supplemented with expert opinion.
Only direct medical costs were considered. Effectiveness
measures were relapse-free patients and patients main-
tained on the same treatment for 2 years. RESULTS:
76.30% of the patients receiving long-acting risperidone
remained relapse-free, compared with 69.60% with olan-
zapine and 47.70% with haloperidol decanoate. Of the
patients treated with long-acting risperidone, 82.7%
remained successfully on treatment for 2 years, compared
with 74.80% and 57.30% for patients treated with olan-
zapine and haloperidol decanoate respectively. Total
direct cost per patient over 2 years were €13,168 with
risperidone, €13,280 with olanzapine, and €16,910 with
haloperidol decanoate. Long-acting risperidone was the
dominant strategy in each case and remained dominant
strategy in sensitivity analyses. CONCLUSION: The
model indicates that treatment with long-acting risperi-
done reduces relapses, improves continuity of treatment,
and is associated with decreased total direct medical costs
over two years, when compared with oral olanzapine and
haloperidol decanoate.
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OBJECTIVE: To develop a health economic model for
estimating long-term costs and effects of treating chronic
venous leg ulcers (VLU) in Sweden on the basis of a 
randomised clinical trial (RCT) (UK-97-0005 Device +
Adaptic(R) (N:37) vs. Adaptic(R) only (N:36) under
Biﬂex(R) compression bandage). METHOD: Patient data
from a Swedish study including 252 VLU-patients
recruited from a specialised leg ulcer clinic in Malmö
between 1993 and 1997, is used in a Monte Carlo simu-
lation model to estimate individual ulcers’ time-to-healing
(TTH) with conventional treatment. In accordance with
patient data for 80 patients matching the inclusion crite-
ria in the UK-97-0005 Device RCT, we impose a lognor-
mal distribution on the TTH. The effect of UK-97-0005
Device is modeled as the relative efﬁcacy of UK-97-0005
Device versus placebo seen in the clinical trial at the end
of the 12 weeks study period (15%, p > 0.05). Costs are
evaluated from a health care provider perspective (mate-
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rials, labour and surgical procedures) and are dependent
on TTH. RESULTS: After 18,000 iterations the average
TTH (cost) fell from 25.9 (€2136) to 22.0 weeks (€1987)
for small ulcers (<10cm2) and from 39.0 (€7047) to 33.0
weeks (€6362) for large ulcers (>=10cm2) when UK-97-
0005 Device was added. Corresponding coefﬁcients of
variation ranged between 99% and 125% for TTH and
86% and 120% for costs. The main cost driver was
labour costs (75% and 84% for small and large ulcers,
respectively). The remaining costs were split equally on
materials and surgical procedures. Break-even was
reached at a relative efﬁcacy of UK-97-0005 Device of
7%. On the basis of an average prevalence of VLU of
0.2% in Sweden, the total cost of treating VLU-patients
with UK-97-0005 Device was estimated to €59.7 million.
CONCLUSION: At a relative efﬁcacy above 7%, UK-97-
0005 Device was shown to be a dominant alternative
compared to conventional treatment of VLU in Sweden.
INPATIENT—RELATED STUDIES
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OBJECTIVES: Sirolimus-eluting coronary stents (SES)
are able to strikingly reduce instent restenoses as com-
pared with conventional bare metal stents (BMS) and
entered the European market in April 2002. We thus
aimed at estimating SES expected economic impact on the
national health-care system (NHS) in Italy. METHODS:
A decision model was developed in Excel and four revas-
cularization strategies were compared (PTCA, BMS, SES,
CABG) in a population of patients with new stenoses in
native coronary arteries. Four subgroups of lesions were
studied, either single-vessel (small vessel, long lesion, 
Benestent-like lesion) or multivessel. Diabetics were sep-
arately analyzed. Incremental cost per revascularization
avoided and cost per event-free year gained were calcu-
lated at a 1 and 5-year time frame and 3% discount rate
was applied to both costs and efﬁcacy. Input data were
from the published trials: BARI, BENESTENT I&II,
ARTS, RAVEL. A survey of 3298 patients in 3 cathlabs
captured the real-life casemix and current practice and
allowed to customize the model. Italian NHS charges
were used to estimate the ﬁnancial impact. RESULTS: In
the ﬁrst year after revascularization, as compared with
BMS, SES averted 123–182 revascularizations in 1000
patients and gained 0.6–1.9 event-free months per
patient; SES also saved €1036–€1800 per patient: a larger
gain was achieved in those with multivessel disease and
in the 5-year horizon, provided that the SES efﬁcacy was
constant over time. In diabetics the SES averted 15%
more revascularizations and increased savings by 12%.
In single vessel disease the breakeven point of SES efﬁ-
cacy was 72% and that of charge for stenting with SES
was €7242 (17% higher than baseline). Overall fore-
casted savings to the NHS would be €38.927.652 per
year, if SES replaced all the stents. CONCLUSIONS: SES
is cost saving in a DRG-based reimbursement NHS,
however, the uptake of SES can be supported through
substantial update of charges while keeping a net eco-
nomic gain.
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OBJECTIVES: A recent study in cardiac surgery showed
a decrease in infections and mortality in patients receiv-
ing leukocyte-depleted erythrocytes (LD) compared 
to buffy-coat depleted packed red blood cells (PC).
However, cost-effectiveness data on leukoreduction of red
blood cell concentrates is scarce. We estimated cost-
effectiveness of LD over PC from a clinical trial involv-
ing valve and CABG surgery patients, from the hospital
perspective. METHODS: From May 1999 to May 2001,
in two university hospitals (Amsterdam and Leiden,
Netherlands), 496 adult patients undergoing cardiac
valve surgery (±CABG) were randomised double-blind
into two groups (LD or PC). The rates of in-hospital mor-
tality and mortality within 90 days after surgery were
primary endpoints. Cost-effectiveness in net costs per 
life-year gained (LYG) was established using standard
pharmaco-economic methods. RESULTS: In-hospital
mortality was 10.1% and 5.5% for PC and LD respec-
tively (OR 0.99–4.00; p = 0.05). Mortality in 90 days was
12.7% and 8.4% for PC and LD respectively (OR
0.84–2.73; p = 0.16). Average costs of ICU-care, standard
care, antibiotics and blood product utilisation were
€11,863.07 and €10,914.02 for PC and LD respectively.
Relative to PC, LD yields an estimated 2.15 un-
discounted LYG (0.70y at 3%, 0.21y at 5%). Ergo, net
costs are lower for LD and health outcomes better. CON-
CLUSIONS: From this clinical trial involving cardiac
surgery patients undergoing valve surgery with or
without CABG, leukodepleting red blood cell concen-
trates appears to be a dominant strategy in this prelimi-
nary evaluation.
